In 2019, Xu et al. (2019) used the CRISPR genome editing system to ablate the CCR5 gene ex vivo in CD34+ hematopoietic stem and progenitor cells and successfully transplanted them back to a patient with HIV and acute lymphoblastic leukemia. This evidence concerns the gene CCR5 and acute lymphoblastic leukemia.